Scholar Rock jumps 12% after FDA approves isembyld for spinal muscular atrophy (SRRK:NASDAQ)
· seekingalpha.com
Scholar Rock (SRRK) jumps after FDA approves Isembyld for SMA.
Scholar Rock Holding (SRRK) surged 12% in extended trading Friday after the Food and Drug Administration approved isembyld, the company’s treatment for spinal...